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Graphical abstract 17 
Half-sandwich Cp*Rh(III) and Cp*Ir(III) complexes have been synthesized with N-Nʹ azine 18 
Schiff-base ligands and characterized by spectroscopic techniques. The molecular structures of 19 
some of the representative complexes have been confirmed by single crystal X-ray analysis. 20 
Chemo-sensitivity activities of the complexes were evaluated against HT-29 (human colorectal 21 
cancer) cell line and non-cancer cell line ARPE-19 (human retinal epithelial cells). 22 
 23 
 24 
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Abstract 27 
The reaction of [Cp*MCl2]2 (M = Rh/Ir) with N-Nʹ azine Schiff-base ligands (L1-L4) 28 
leads to the formation of mononuclear cationic half-sandwich complexes having the general 29 
formula [Cp*M(L)Cl]+ (1–8), (M = Rh/Ir and L = (2-hydroxy-4-methoxybenzylidene)2-30 
pyridylamidrazone (L1), (2-hydroxybenzylidene)2-pyridylamidrazone (L2), (1-(2-31 
hydroxyphenyl)ethylidene)2-pyridylamidrazone (L3) and (1-phenylethylidene)2-32 
pyridylamidrazone (L4). All these complexes were isolated as their hexafluorophosphate salts 33 
and fully characterized by spectroscopic and analytical techniques. The molecular structure of 34 
complexes (1), (3), (4), (7) and (8) have been determined by single crystal X-ray crystallographic 35 
studies which displayed the coordination of the ligand to the metal in a bidentate N∩N fashion 36 
through nitrogen atom of pyridine and one azine nitrogen. The chemo-sensitivity activities of the 37 
complexes were evaluated against HT-29 (human colorectal cancer) cell line and non-cancer cell 38 
line ARPE-19 (human retinal epithelial cells) which revealed that the complexes are moderately 39 
cytotoxic to cancer cells over human cells although complex 5 was the most potent among all the 40 
compounds. Theoretical studies carried out using DFT and TD-DFT at B3LYP level shows good 41 
agreement with the experimental results. 42 
Keywords: Rhodium, Iridium, Azine Schiff-base ligands, Cytotoxicity 43 
  44 
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1. Introduction 45 
The chemistry of half-sandwich organometallic complexes has evolved as a versatile 46 
subject of research during the past few decades due to its wide application in biological and 47 
medicinal fields [1-4]. Organometallic half-sandwich compounds of the general formula 48 
[Cp*MCl(LLʹ)] (M = Rh, Ir and LL' = N,N or N,O donor ligands) have been extensively studied 49 
for their cytostatic activity, DNA binding, cellular uptake and as DNA intercelators [5-9]. 50 
Rhodium and iridium complexes have also been investigated as an alternative to platinum based 51 
drugs mainly because of their water solubility and lability towards ligand exchange [10, 11]. 52 
Recently Therrien et.al reported dinuclear dithiolato bridged rhodium and iridium complexes 53 
which exhibit cytotoxicity against human ovarian cancer cells lines (A2780 and A2780cisR) 54 
[12]. C-H activated cyclometallated Rh(III) and Ir(III) complexes can effectively bind to DNA 55 
and protein through electrostatic and hydrophobic interactions [13]. Iridium complexes of 56 
dihydroxybipyridine are active catalysts for homogenous water oxidation under mild reaction 57 
conditions [14]. Rh(III) and Ir(III) polypyridyl complexes exhibits strong antiproliferative 58 
activity towards human cancer cell lines and are also capable of binding to DNA [15]. A number 59 
of half-sandwich Ir(III) complexes have been reported by Sadler et al with chelating C, N and 60 
pyridine ligands and N, N donor ligands which showed strong antiproliferative activity  [16, 17]. 61 
Pyridyl azines represent an important class of organic compounds with interesting 62 
properties having wide applications in various areas [18]. Open chain diazine Schiff base ligands 63 
linked by a single N-N bond are of great interest due to its rotational flexibility around the N-N 64 
bond and potential donor sites which can give rise to a rich variety of coordination compounds 65 
with different binding modes [19]. The N-N bridging ligand plays a crucial role in 66 
communicating the metal centers to form mononuclear, dinuclear or polynuclear complexes [20]. 67 
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The diazine ligand has been employed into several transition metal azido and thiocyanato 68 
systems namely Mn(II)-azido, Cd(II)-NCS to obtain several 1D, 2D and 3D polymers which 69 
exhibit interesting magnetic properties [21, 22]. Dinuclear transition metal complexes of Cu, Zn, 70 
Mn and Ni have been reported with bridging N-N diazine ligands which give rise to strong 71 
ferromagnetic and antiferromagnetic coupling [23]. In the recent years our group has reported 72 
many half-sandwich Ru(II), Rh(III) and Ir(III) complexes with azine ligands [24, 25]. In 73 
continuation with our interest of these ligands herein we report four new azine Schiff base 74 
ligands derived from 2-pyridylamidrazone and its corresponding rhodium and iridium half-75 
sandwich metal complexes. The complexes were tested for their cytotoxic property to selectively 76 
kill HT-29 cancer cell line against normal ARPE-19 cells. 77 
2. Experimental Section 78 
2. 1. Physical methods and materials 79 
All the reagents were purchased from commercial sources and used as received. Starting 80 
materials RhCl3.nH2O, IrCl3.nH2O were purchased from Arora Matthey limited. 2-81 
cyanopyridine, 2-hydroxybenzaldehyde, 2-hydroxyacetophenone, were obtained from Aldrich, 82 
acetophenone and 2-hydroxy-4-methoxybenzaldehyde were obtained from Alfa-Aesar. The 83 
solvents were purified and dried according to standard procedures [26]. All the reactions were 84 
carried out under normal conditions. The starting precursor metal complexes [Cp*MCl2]2 (M = 85 
Rh/Ir) were prepared according to the literature methods [27]. Infrared spectra were recorded on 86 
a Perkin-Elmer 983 spectrophotometer by using KBr pellets in the range of 400-4000 cm-1. 1H 87 
NMR spectra were recorded on a Bruker Avance II 400 MHz spectrometer using DMSO-d6 and 88 
CDCl3 as solvents. Absorption spectra were recorded on a Perkin-Elmer Lambda 25 UV/Visible 89 
spectrophotometer in the range of 200-800 nm at room temperature in acetonitrile. Elemental 90 
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analyses of the complexes were performed on a Perkin-Elmer 2400 CHN/S analyzer. Mass 91 
spectra were recorded using Q-Tof APCI-MS instrument (model HAB 273). All these 92 
mononuclear metal complexes were synthesized and characterized by using FT-IR, 1H NMR, 93 
UV-Vis, and Single-crystal X-ray diffraction techniques. 94 
2. 2. Single-crystal X-ray structures analyses 95 
The orange crystals of complexes (1), (3), (7) and (8) were obtained by slow diffusion of 96 
hexane into acetone or DCM solution and yellow crystals of complex (4) was obtained by 97 
diffusing hexane into DCM solution. Single crystal X-ray diffraction data for all the complexes 98 
(1), (3) (4), (7) and (8) were collected on a Oxford Diffraction Xcalibur Eos Gemini 99 
diffractometer at 293 K using graphite monochromated Mo-Kα radiation (λ = 0.71073 Å). The 100 
strategy for the data collection was evaluated using the CrysAlisPro CCD software. Crystal data 101 
were collected by standard ‘‘phi–omega scan’’ techniques and were scaled and reduced using 102 
CrysAlisPro RED software. The structures were solved by direct methods using SHELXS-97 103 
and refined by full-matrix least squares with SHELXL-97 refining on F2 [28, 29]. The positions 104 
of all the atoms were obtained by direct methods. Metal atoms in the complex were located from 105 
the E-maps and non-hydrogen atoms were refined anisotropically. The hydrogen atoms bound to 106 
the carbon were placed in geometrically constrained positions and refined with isotropic 107 
temperature factors, generally 1.2 Ueq of their parent atoms. Crystallographic and structure 108 
refinement details for the complexes are summarized in Table 1, and selected bond lengths and 109 
bond angles are presented in Table S1. Figures 1-3 were drawn with ORTEP3 program.  Figure 4 110 
and Figures S3-S6 were drawn with MERCURY3.6 program [30]. 111 
2.3. Biological studies 112 
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All complexes (1-8) were dissolved in DMSO at 100 mM and stored at -20 °C until 113 
needed. The complexes were tested against cancer cell line HT-29 (human colorectal cancer), 114 
and one non-cancer cell line ARPE-19 (human retinal epithelial cells). Cells were seeded into 96 115 
well plates at 1 x 103 cells per well and incubated at 37 °C in a CO2 enriched (5%), humidified 116 
atmosphere overnight to adhere. The cells were exposed to a range of drug concentrations in the 117 
range of 0-100 µM for four days before cell survival was determined using the MTT assay [31]. 118 
To each well MTT (0.5 mg/ml) was added and was further incubated at 37 °C for 4 h. After this 119 
the MTT was removed from each well and the formazan crystals formed were dissolved in 150 120 
µM DMSO. The absorbance of the resulting solution was recorded at 550 nm using an ELISA 121 
spectrophotometer. The percentage of cell inhibition was calculated by dividing the absorbance 122 
of treated cell by the control value absorbance (exposed to 0.1 % DMSO). The results were 123 
expressed in terms of IC50 values (concentration required to kill 50 % cell) and all studies were 124 
performed in triplicate. The results were also expressed in terms of a ‘selectivity index’ defined 125 
as the IC50 of the non-cancer cell line ARPE divided by the IC50 of cancer cell lines [32]. Values 126 
greater than 1 demonstrate that the compound is preferentially active against tumor cell 127 
compared to normal cell lines. 128 
2.4. Computational methodology 129 
All the electronic structure calculations of the metal complexes (1-8) were carried out 130 
using the Gaussian 09 suite of program [33]. The geometries of the rhodium and iridium 131 
complexes were optimized in the gas phase employing the DFT-based B3LYP method with 6-132 
31G** basis set for (H, C, N, O, Cl, F and P atoms and LANL2DZ [34, 35] for (Rh and Ir) 133 
atoms. Harmonic frequency calculations were carried out at the same level of theory to ensure 134 
that the optimized geometries were true minima on the potential energy surface (PES). Natural 135 
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Bond Orbital (NBO) analysis [36] was used to obtain the charge distribution on individual atoms 136 
and the d-orbital occupations of the metal present in the complexes. Time dependent-Density 137 
Functional Theory (TD-DFT) [37] has been employed to evaluate the absorption spectra and the 138 
electronic transitions of the metal complexes. In order to incorporate the effect of the solvent 139 
around the molecule, the Polarizable Continuum Model (PCM) [38] was used in TD-DFT 140 
calculations. The percentage contribution of molecular orbital analysis was carried out using 141 
Chemissian software package [39]. 142 
2.4. General procedure for preparation of ligands 1-4 143 
2.4.1. The azine Schiff base ligands (L1-L4) were prepared by two step procedure. 144 
In the first step 2-pyridylamidrazone was prepared, by following a reported procedure 145 
[40]. 2-cyanopyridine and hydrazine hydrate were dissolved and stirred in absolute ethanol 146 
overnight to give 2-pyridylamidrazone as yellow crystalline solid which was used in the next 147 
step without further purification (Scheme-1). In the second step (5 mmol) of aldehyde or ketone 148 
and 2-pyridylamidrazone (5 mmol) was refluxed in 10 ml ethanol for 5 hours (Scheme-2). The 149 
products obtained after cooling the solution were filtered off washed with cold methanol and 150 
diethyl ether and dried in vacuum. 151 
Data for ligands (L1-L4) 152 
2.4.2. (2-hydroxy-4-methoxybenzylidene)2-pyridylamidrazone (L1) 153 
Color: Yellow needles; Yield: 88%; IR (KBr, cm-1): 3487(s), 3380(s), 3333(m), 2964(m), 154 
1627(s), 1587(m), 1566(m), 1394(m), 1340(s); 1H NMR (400 MHz, CDCl3): δ = 11.82 (s, 1H, 155 
OH), 8.60 (s, 1H, CH(imine)), 8.57 (d, 1H, J = 4.0 Hz, CH(py)), 8.34 (d, 1H, J = 8.0 Hz, CH(py)), 156 
7.76 (t, 1H, CH(py)), 7.35 (t, 1H, CH(py)), 7.20 (d, 2H, J = 8.0 Hz, CH(Ar)), 6.46-6.50 (m, 3H, NH2, 157 
CH(Ar)), 3.80 (s, 3H, OMe); HRMS-APCI (m/z): 271.11 [M+H]+; UV–Vis {Acetonitrile, λmax, 158 
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nm (ε/10-4 M-1 cm-1)}: 218 (0.84), 314 (0.68), 342 (0.92), 355 (0.94); Anal. Calc. for C14H14N4O2 159 
(270.29): C, 62.21; H, 5.22; N, 20.73. Found: C, 62.36; H, 5.35; N, 20.86%. 160 
 2.4.3. (2-hydroxybenzylidene)2-pyridylamidrazone (L2) 161 
Color: Yellow needles; Yield: 92%; IR (KBr, cm-1): 3477(s), 3363(s), 3340(s), 3043(m), 1626(s), 162 
1576(m), 1567(m), 1473(m), 1337(m); 1H NMR (400 MHz, CDCl3): δ = 11.61 (s, 1H, OH), 8.59 163 
(s, 1H, CH(imine)), 8.54 (d, 1H, J = 4.0 Hz, CH(py)), 8.28 (d, 1H, J = 8.0 Hz, CH(py)), 7.74 (t, 1H, 164 
CH(py)), 7.33 (t, 1H, CH(py)), 7.24-7.27 (m, 3H, NH2, CH(Ar)), 6.96 (d, 1H, J = 8.0 Hz, CH(Ar)), 165 
6.87 (t, 2H, CH(Ar)); HRMS-APCI (m/z): 241.10 [M+H]+; UV–Vis {Acetonitrile, λmax, nm (ε/10-4 166 
M-1 cm-1)}: 219 (0.84), 247 (0.55), 349 (1.30), 361 (1.29); Anal. Calc. for C13H12N4O (240.26): 167 
C, 64.99; H, 5.03; N, 23.32. Found: C, 65.12; H, 5.18; N, 23.44%. 168 
2.4.4. (1-(2-hydroxyphenyl)ethylidene)2-pyridylamidrazone (L3) 169 
Color: Yellow crystalline solid; Yield: 95%; IR (KBr, cm-1): 3482(s), 3339(s), 3056(m), 170 
3003(m), 1615(s), 1562(m), 1507(m), 1300(m); 1H NMR (400 MHz, CDCl3): δ = 13.73 (s, 1H, 171 
OH), 8.59 (d, 1H, J = 4.0 Hz, CH(py)), 8.36 (d, 1H, J = 8.0 Hz, CH(py)), 7.79 (t, 1H, CH(py)), 7.58 172 
(t, 1H, CH(py)), 7.21-7.28 (m, 3H, NH2, CH(Ar)), 6.98 (d, 2H, J = 8.0 Hz, CH(Ar)), 6.89 (t, 1H, 173 
CH(Ar)), 2.62 (s, 3H, CH3); HRMS-APCI (m/z): 255.12 [M+H]+; UV–Vis {Acetonitrile, λmax, nm 174 
(ε/10-4 M-1 cm-1)}: 217 (1.21), 303 (0.74), 344 (0.95); Anal. Calc. for C14H14N4O (254.29): C, 175 
66.13; H, 5.55; N, 22.03. Found: C, 66.25; H, 5.68; N, 22.21%. 176 
2.4.5. (1-phenylethylidene)2-pyridylamidrazone (L4) 177 
Color: Yellow crystalline solid; Yield: 92%; IR (KBr, cm-1): 3450(s), 3331(s), 3056(m), 178 
3009(m), 1604(s), 1568(m), 1445(m), 1362(m); 1H NMR (400 MHz, CDCl3): δ = 8.58 (d, 1H, J 179 
= 4.0 Hz, CH(py)), 8.23 (d, 1H, J = 8.0 Hz, CH(py)), 7.71 (t, 1H, CH(py)), 7.30 (t, 1H, CH(py)), 7.21-180 
7.28 (m, 3H, NH2, CH(Ar)), 6.93 (m, 3H, CH(Ar)), 6.89 (t, 1H, CH(Ar)), 2.39 (s, 3H, CH3); HRMS-181 
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APCI (m/z): 239.13 [M+H]+; UV–Vis {Acetonitrile, λmax, nm (ε/10-4 M-1 cm-1)}: 225 (0.21), 327 182 
(0.29); Anal. Calc. for C14H14N4 (238.29): C, 70.57; H, 5.92; N, 23.51. Found: C, 70.72; H, 6.03; 183 
N, 23.62%. 184 
2.5. General procedure for preparation of metal complexes (1-8) 185 
A mixture of metal precursor [Cp*MCl2]2 (M = Rh/Ir) (0.1 mmol), azine Schiff-base ligands (L1-186 
L4) (0.2 mmol) and 2.5 equivalents of NH4PF6 in dry methanol (10 ml) was stirred at room 187 
temperature for 8 hours (Scheme-3). The solvent was evaporated under reduced pressure, and the 188 
residue was dissolved in dichloromethane and filtered over celite to remove excess salt. The 189 
filtrate was reduced to 2 ml and diethyl ether was added to induce precipitation. The yellow 190 
colored precipitate, which formed, was filtered and washed with diethyl ether and dried in 191 
vacuum. 192 
2.5.1. [Cp*Rh(L1)Cl]PF6 (1) 193 
Yield: 56 mg (40%); IR (KBr, cm-1): 3460(m), 3237(m), 2926(w), 1630(s), 1595(m), 1296(m), 194 
846(s); 1H NMR (400 MHz, CDCl3): δ = 10.5 (s, 1H, OH), 9.02 (s, 1H, CH(imine)), 8.76 (d, 1H, J 195 
= 4.0 Hz, CH(py)), 8.54 (d, 1H, J = 4.0 Hz, CH(py)), 8.13 (t, 1H, CH(py)), 7.76 (t, 1H, CH(py)), 7.41 196 
(d, 1H, J = 8.0 Hz, CH(Ar)), 7.38 (s, 2H, NH2), 6.53 (d, 1H, J = 8.0 Hz, CH(Ar),), 6.50 (s, 1H, 197 
CH(Ar)), 3.81 (s, 3H, OMe), 1.58 (s, 15H, CH(Cp*)); HRMS-APCI (m/z): 507.12 [M-PF6-HCl]+; 198 
UV–Vis {Acetonitrile, λmax, nm (ε/10-4 M-1 cm-1)}: 233 (0.98), 277 (0.57), 352 (0.42); Anal. 199 
Calc. for C24H29ClF6N4O2PRh (688.84): C, 41.85; H, 4.24; N, 8.13. Found: C, 41.96; H, 4.16; N, 200 
8.23%. 201 
2.5.2. [Cp*Ir(L1)Cl]PF6 (2) 202 
Yield: 70 mg (45%); IR (KBr, cm-1): 3447(m), 3241(m), 2925(m), 1630(s), 1610(m), 1293(m), 203 
846(s); 1H NMR (400 MHz, CDCl3): δ = 10.4 (s, 1H, OH), 9.02 (s, 1H, CH(imine)), 8.77 (d, 1H, J 204 
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= 4.0 Hz, CH(py)), 8.51 (d, 1H, J = 4.0 Hz, CH(py)), 8.17 (t, 1H, CH(py)), 7.78 (t, 1H, CH(py)), 7.42 205 
(d, 1H, J = 8.0 Hz, CH(Ar)), 7.39 (s, 2H, NH2), 6.56 (d, 1H, J = 8.0 Hz, CH(Ar)), 6.54 (s, 1H, 206 
CH(Ar)), 3.87 (s, 3H, OMe), 1.62 (s, 15H, CH(Cp*)); HRMS-APCI (m/z): 597.18 [M-PF6-HCl]+; 207 
UV–Vis {Acetonitrile, λmax, nm (ε/10-4 M-1 cm-1)}: 266 (0.36), 347 (0.29); Anal. Calc. for 208 
C24H29ClF6N4O2PIr (778.14): C, 37.04; H, 3.76; N, 7.20. Found: C, 37.19; H, 3.89; N, 7.31%. 209 
2.5.3. [Cp*Rh(L2)Cl]PF6 (3) 210 
Yield: 52 mg (39%); IR (KBr, cm-1): 3422(m), 3310(w), 2923(w), 1636(s), 1603(m), 1457(m), 211 
845(s); 1H NMR (400 MHz, CDCl3): δ = 10.1 (s, 1H, OH), 9.11 (s, 1H, CH(imine)), 8.78 (d, 1H, J 212 
= 4.0 Hz, CH(py)), 8.49 (d, 1H, J = 8.0 Hz, CH(py)), 8.14 (t, 2H, CH(py)), 7.78 (t, 1H, CH(Ar)), 7.60 213 
(d, 1H, J = 8.0 Hz, CH(Ar)), 7.38 (s, 2H, NH2), 6.92-7.01 (m, 2H, CH(Ar)), 1.58 (s, 15H, CH(Cp*)); 214 
HRMS-APCI (m/z): 477.12 [M-PF6-HCl]+; UV–Vis {Acetonitrile, λmax, nm (ε/10-4 M-1 cm-1)}: 215 
235 (1.55), 283 (0.79), 348 (1.00); Anal. Calc. for C23H27ClF6N4OPRh (658.81): C, 41.93; H, 216 
4.13; N, 8.50. Found: C, 42.08; H, 4.25; N, 8.68%. 217 
2.5.4. [Cp*Ir(L2)Cl]PF6 (4) 218 
Yield: 52 mg (34%); IR (KBr, cm-1): 3479(s), 3329(s), 2924(w), 1642(s), 1618(m), 1602(m), 219 
842(s); 1H NMR (400 MHz, CDCl3): δ = 10.1 (s, 1H, OH), 9.13 (s, 1H, CH(imine)), 8.80 (d, 1H, J 220 
= 4.0 Hz, CH(py)), 8.56 (d, 1H, J = 8.0 Hz, CH(py)), 8.18 (t, 2H, CH(py)), 7.80 (t, 1H, CH(Ar)), 7.64 221 
(d, 1H, J = 8.0 Hz, CH(Ar)), 7.40 (s, 2H, NH2), 6.99-7.35 (m, 2H, CH(Ar)), 1.63 (s, 15H, CH(Cp*)); 222 
HRMS-APCI (m/z): 567.17 [M-PF6-HCl]+; UV–Vis {Acetonitrile, λmax, nm (ε/10-4 M-1 cm-1)}: 223 
291 (0.62), 344 (0.78); Anal. Calc. for C23H27ClF6N4OPIr (748.12): C, 36.93; H, 3.64; N, 7.49. 224 
Found: C, 37.11; H, 3.83; N, 7.62%. 225 
2.5.5. [(Cp*Rh(L3)Cl]PF6 (5) 226 
  
12 
 
Yield: 58 mg (43%); IR (KBr, cm-1): 3452(s), 3318(s), 2924(m), 1648(s), 1600(m), 1566(m), 227 
1489(m), 842(s); 1H NMR (400 MHz, DMSO-d6): δ = 12.5 (s, 1H, OH), 8.96 (d, 1H, J = 4.0 Hz, 228 
CH(py)), 8.33-8.38 (m, 3H, CH(py)), 7.91 (t, 1H, CH(Ar)), 7.86 (d, 1H, J = 8.0 Hz, CH(Ar)), 7.48 (t, 229 
1H, J = 8.0 Hz, CH(Ar)), 7.01-7.06 (m, 3H, NH2, CH(Ar)), 2.48 (s, 3H, CH3), 1.59 (s, 15H, 230 
CH(Cp*)); HRMS-APCI (m/z): 491.14 [M-PF6-HCl]+; UV–Vis {Acetonitrile, λmax, nm (ε/10-4 M-1 231 
cm-1)}: 229 (0.95), 268 (0.59), 332 (0.32); Anal. Calc. for C24H29ClF6N4OPRh (672.84): C, 232 
42.84; H, 4.34; N, 8.33. Found: C, 42.98; H, 4.26; N, 8.48%. 233 
2.5.6. [Cp*Ir(L3)Cl]PF6 (6) 234 
Yield: 65 mg (42%); IR (KBr, cm-1): 3460(m), 3237(m), 2926(w), 1630(s), 1595(m), 1296(m), 235 
846(s), 3456(m), 3369(m), 2925(m), 1649(s), 1618(m), 1598(m), 1306(m), 845(s); 1H NMR 236 
(400 MHz, DMSO-d6): δ = 12.3 (s, 1H, OH), 8.94 (d, 1H, J = 4.0 Hz, CH(py)), 8.44 (d, 1H, J = 237 
4.0 Hz, CH(py)), 8.35 (t, 2H, CH(py)), 7.90 (t, 1H, CH(Ar)), 7.86 (d, 1H, J = 8.0 Hz, CH(Ar)), 7.48 (t, 238 
1H, CH(Ar)), 7.01-7.06 (m, 3H, NH2, CH(Ar)), 2.46 (s, 3H, CH3), 1.58 (s, 15H, CH(Cp*)); HRMS-239 
APCI (m/z): 581.19 [M-PF6-HCl]+; UV–Vis {Acetonitrile, λmax, nm (ε/10-4 M-1 cm-1)}: 209 240 
(1.27), 263 (0.66), 330 (0.36); Anal. Calc. for C24H29ClF6N4OPIr (762.15): C, 37.82; H, 3.84; N, 241 
7.35. Found: C, 37.96; H, 3.96; N, 7.44%. 242 
2.5.7. [(Cp*Rh(L4)Cl]PF6 (7) 243 
Yield: 54 mg (41%); IR (KBr, cm-1): 3441(s), 3137(m), 2961(w), 1640 (s), 1593(m), 1464(m), 244 
841(s); 1H NMR (400 MHz, DMSO-d6): δ = 8.96 (d, 1H, J = 4.0 Hz, CH(py)), 8.33-8.37 (m, 2H, 245 
CH(py)), 7.88 (t, 1H, CH(py)), 7.81 (d, 1H, J = 8.0 Hz, CH(Ar)), 7.46 (t, 1H, CH(Ar)), 7.23-7.28 (m, 246 
2H, CH(Ar)), 6.97-7.02 (m, 3H, NH2, CH(Ar)), 2.47 (s, 3H, CH3), 1.59 (s, 15H, CH(Cp*)); HRMS-247 
APCI (m/z): 511.12 [M-PF6]+; UV–Vis {Acetonitrile, λmax, nm (ε/10-4 M-1 cm-1)}: 229 (1.37), 248 
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265 (0.37), 400 (0.22); Anal. Calc. for C24H29ClF6N4PRh (656.84): C, 43.89; H, 4.45; N, 8.53. 249 
Found: C, 44.02; H, 4.39; N, 8.61%. 250 
2.5.8. [Cp*Ir(L4)Cl]PF6 (8) 251 
Yield: 65 mg (43%); IR (KBr, cm-1): 3458(s), 3383(s), 2922(m), 1643(s), 1603(m), 1567(m), 252 
1447(m), 844(s); 1H NMR (400 MHz, DMSO-d6): δ = 8.97 (d, 1H, J = 4.0 Hz, CH(py)), 8.31-8.34 253 
(m, 2H, CH(py)), 7.85 (t, 1H, CH(py)), 7.79 (d, 1H, J = 8.0 Hz, CH(Ar)), 7.44 (t, 1H, CH(Ar)), 7.19-254 
7.23 (m, 2H, CH(Ar)), 6.99-7.03 (m, 3H, NH2, CH(Ar)), 2.46 (s, 3H, CH3), 1.59 (s, 15H, CH(Cp*)); 255 
HRMS-APCI (m/z): 601.17 [M-PF6]+; UV–Vis {Acetonitrile, λmax, nm (ε/10-4 M-1 cm-1)}: 256 256 
(0.53), 361 (0.20); Anal. Calc. for C24H29ClF6N4PIr (746.15): C, 38.63; H, 3.92; N, 7.51. Found: 257 
C, 38.74; H, 4.03; N, 7.63%. 258 
3. Results and discussion 259 
3.1. Synthesis of ligands and complexes 260 
The azine Schiff-base ligands (L1-L4) were prepared by the reaction of 2-261 
pyridylamidrazone and the respective aldehyde or ketone in absolute ethanol medium. The 262 
complexes (1-8) were synthesized by the reaction of Rh/Ir metal precursors with the azine 263 
Schiff-base ligands. The cationic complexes were isolated with PF6 counter ion. All these metal 264 
complexes were obtained in good yields and are yellow in color. They are stable in air as well as 265 
in solid state, and are non-hygroscopic. These complexes are soluble in common organic 266 
solvents such as dichloromethane, acetonitrile and acetone but insoluble in diethyl ether and 267 
hexane. All the synthesized ligands and complexes were fully characterized by spectroscopic 268 
techniques. 269 
3.2. Spectroscopic characterization of ligands 270 
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The infrared spectra of the free ligand shows characteristic stretching frequencies for 271 
NH2, OH, C=N and C=C groups. The NH2 and OH stretching frequencies for the azine ligand 272 
appeared in the range of 3300-3500 cm-1. The C=C and C=N stretching frequencies were 273 
observed in the range of 1550-1626 cm-1. The proton NMR spectra of the ligands displayed 274 
signals in the range of 7.30-8.57 ppm assignable to the protons of the pyridine ring. The imine 275 
protons for L1 and L2 are located at 8.60 and 8.59 ppm respectively. The methoxy proton signal 276 
was observed as a singlet for L1 at 3.80 ppm. The methyl protons of L3 and L4 were observed as 277 
a singlet at 2.62 and 2.39 ppm respectively. The hydroxyl proton resonance for the ligands 278 
appeared in the range of 11.5-11.9 ppm. The aromatic protons of the ligand appeared as doublet, 279 
triplet and multiplet in the range of 6.21-7.29 ppm. The [M+H]+ molecular ion peak for the 280 
ligands are shown in the experimental section which are found to be in good agreement with the 281 
expected range. The electronic spectra of the free ligands are shown in (Figure S1). The 282 
electronic spectra of the free ligands show absorption bands in the range of 210-360 nm. The 283 
band in the range of 210-250 nm can be assigned as pi-pi* and n-pi * transition. The band around 284 
300-370 nm is due to the intermolecular charge transfer transition within the whole molecule 285 
[41]. 286 
3.3. Spectroscopic characterization of complexes 287 
The IR spectra of the complexes show sharp bands around 842-846 cm-1 due to the P-F 288 
stretching frequency of the counter ion [42]. The OH and NH2 stretching vibrations in the 289 
complexes were found around 3300-3500 cm-1. The retaining of the OH and NH2 stretching 290 
frequencies indicates that they are not involved in bonding to the metal center. The strong 291 
absorption band for νC=N around 1630-1650 cm-1 at higher wave numbers as compared to the free 292 
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ligand around 1615-1626 cm-1 suggest that the coordination to the metal occurs through the 293 
imine and pyridine nitrogen.  294 
The proton NMR spectra of the metal complexes show that the ligand resonance signals 295 
are shifted downfield as compared to that of the free ligand. These signals are shifted downfield 296 
because of the ligand coordination to the metal atom. The imine proton signal was observed in 297 
the range of 9.0-9.13 ppm for complexes (1-4). The hydroxyl proton resonance for the 298 
complexes appeared in the range of 10.1-12.5 ppm respectively. The appearance of the hydroxyl 299 
proton signal indicates that the hydroxyl group is not involved in bonding to the metal atom. The 300 
pyridine ring protons also showed downfield signals comprising of doublet and triplet in the 301 
range of 7.75-8.96 ppm. The NH2 protons were observed as a singlet for complexes (1-4) in the 302 
range of 7.35-7.37 ppm respectively. The methoxy proton resonance for complexes (1 and 2) 303 
appeared as a singlet at 3.81 and 3.83 ppm. The aromatic proton signals for complexes appeared 304 
in the range of 6.50-7.86 ppm as doublet, triplet and multiplet. The methyl proton signal for 305 
complexes (5-8) appeared as a singlet around 2.46-2.48 ppm respectively. In addition to the 306 
signals for the ligand protons, a sharp singlet was observed for all the complexes between 1.58-307 
1.63 ppm respectively corresponding to the methyl protons of the Cp* ring. In the mass spectra 308 
of the complexes (1–6) the peaks at m/z: 507.12, m/z: 597.18, m/z: 477.12, m/z: 567.17, m/z: 309 
491.13 and m/z: 581.20 can be assigned as [M-PF6-HCl]+ ion peaks respectively. Whereas, the 310 
mass spectra of the complex 7 and 8 displayed molecular ion peaks at m/z: 511.12 and 601.17 311 
which corresponds to the [M-PF6]+ ion. 312 
The electronic spectra of the complexes were recorded in acetonitrile at 10-4 M 313 
concentration at room temperature and the plot is shown in (Figure S2). The electronic spectra of 314 
complexes display two absorption band in the higher energy region around 210-330 nm. The 315 
  
16 
 
bands in the higher energy UV region can be assigned as ligand centered or intra ligand pi-pi* and 316 
n-pi*transition. The Rh(III) and Ir(III) complexes provides filled dpi (t2g) orbitals which can 317 
interact with low lying pi* orbitals (C=N) of the ligand. The band in the lower energy region 318 
around 345-405 nm can be assigned as Rh (dpi) or Ir (dpi) to pi* ligand metal to ligand charge 319 
transfer (MLCT) transition [43]. 320 
3.4. Molecular structures of complexes 321 
The molecular structures of some of the respective complexes have been elucidated by 322 
single crystal X-ray analysis. Suitable single crystals were attached to a glass fibre and 323 
transferred into the Oxford Diffraction Xcalibur Eos Gemini diffractometer. The crystallographic 324 
details and structure refinement details are summarized in Table 1. The geometrical parameters 325 
around the metal atom involving ring centroid are listed in Table S1. In all these complexes the 326 
ligand is coordinated to the metal atom in a similar manner with N∩N binding mode. Complex 327 
(1) and (8) crystallized in triclinic system with space group P 1͞. Complex (8) crystallized with 328 
one PF6 and one chloride counter ion. Complex (3) and (4) crystallized in monoclinic system 329 
with space group P21/c whereas complex (7) crystallized in monoclinic system with space group 330 
P21. 331 
All these complexes display a typical three-legged piano stool geometry around the metal 332 
center with coordination sites occupied by one chloride group, two σ bonded nitrogen atoms 333 
from chelating azine ligand and the pentamethylcyclopentadienyl (Cp*) ring in η5 manner. The 334 
metal atom in all these complexes is situated in a pseudo-octahedral arrangement with the azine 335 
ligand coordinating through the pyridine and azine nitrogen atoms forming a five membered 336 
metallocycle. In complexes (1), (3), (4) and (7) the M-N bond length {2.088(5), 2.099(3), 337 
2.098(4) and 2.102(4) Å} from pyridine is comparatively shorter than the azine nitrogen-metal 338 
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distances {2.135(5), 2.116(3), 2.105(4) and 2.159(4) Å}, which are similar to those, reported 339 
with similar complexes [24, 44]. However in complex (8) the metal-nitrogen distance from 340 
pyridine {2.102(5) Å} is comparatively larger than azine nitrogen-metal distance, which is 341 
{2.096(5) Å}. The C=N bond length of the coordinated nitrogen in complex (1), (3), (4) and (8) 342 
is longer than that of the uncoordinated C=N (Table S1) which could be due to the back bonding 343 
of electron from metal (dpi) to pi* orbital of the ligand. But in complex (7), a reverse pattern has 344 
been observed where the C=N bond length of the coordinated nitrogen {1.346(7) Å} is shorter 345 
than uncoordinated C=N {1.358(7) Å} bond. The average M-C distances are {2.159 (1), 2.1534 346 
(3), 2.1616 (4), 2.1528 (7) and 2.1726 (8) Å} while the distance between the metal to Cp* 347 
centroid ring is in the range of 1.758–1.793 Å respectively. The M-Cl bond lengths {2.3976(15) 348 
(1), 2.4172(9) (3), 2.4190(12) (4), 2.4242(16) (7) and 2.4220(17) (8) shows no significant 349 
differences and is comparable to previously reported values (Table 1) [45-48]. The bite angle 350 
N(1)-Rh(1)-N(2) values are 75.10(19) (1), 75.09(11) (3), and 75.44(17) (7) whereas in complex 351 
(4) and (8) the bite angle values are N(1)-Ir(1)-N(2) values are 74.99(14) (4) and 75.26(18) 352 
respectively which probably indicates an inward bending of the coordinated pyridyl and azine 353 
group [49]. The bond angles N(1)-M-Cl(1) and N(2)-M-Cl(1) in complexes are comparable to 354 
the piano stool arrangement about the metal atom and is comparable to reported values for 355 
closely related systems [50-52]. Further the crystal packing in complex (1) is stabilized by weak 356 
intermolecular hydrogen bonding C-H·····O (2.702 Å) between the hydrogen atom from methoxy 357 
group and oxygen atom of the hydroxyl group and C-H·····Cl (2.793 Å) interaction between CH3 358 
group of Cp* and chloride atom (Figure S3). These interactions play a significant role in the 359 
formation of supramolecular motifs. 360 
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On the other hand in the crystal structure of complex (3) and (4) two types of 361 
intramolecular hydrogen bonding has been observed; the first one between the uncoordinated 362 
nitrogen atom of the azine linkage with the hydrogen atom of the hydroxyl group O-H·····N 363 
(1.916 and 1.908 Å) and the second between the hydrogen atom from NH2 and uncoordinated 364 
azine nitrogen atom N-H·····N (2.323 and 2.328 Å) (Figure 4). The selected hydrogen bonding 365 
distances and angles for complex (3) and (4) are given in (Table 2). Also the crystal packing in 366 
complex (3) and (4) is further stabilized by two different C-H·····Cl interaction between the Cl 367 
atom attached to metal M (where M = Rh/Ir) with hydrogen atom of pyridine ring and NH2 368 
(Figure S4). Complex (7) shows C-H·····pi (2.832 and 2.937 Å) interactions between the methyl 369 
hydrogen atom and Cp* moiety and between pyridine ring and hydrogen atom of Cp* group 370 
respectively (Figure S5). Interestingly the crystal packing in complex (8) leads to a dimeric unit 371 
via intermolecular C-H·····Cl interaction between the chloride counter ion and hydrogen atom 372 
from pyridine ring, NH2 and Cp* group (Figure S6). 373 
3.5. Chemosensitivity studies 374 
The complexes (1-8) were tested for their cytotoxicity against cancer cell line HT-29 375 
(human colorectal cancer), and non-cancer cell line ARPE-19 (human retinal epithelial cells). 376 
The response of the cell lines HT-29 to the test complexes and cisplatin (1-8) is presented in 377 
graphical form in Figure 5 and in tabular form in Table 3. All the complexes tested were found to 378 
be active against HT-29 cancer cell line (IC50< 30 µM). Complex (5) was the most potent among 379 
all the complexes with (IC50 value of 96.93 ± 5.31 µM). However all the complexes were less 380 
potent than cisplatin (IC50 value of 0.25 ± 0.11 µM against HT-29). The selectivity index (SI) 381 
defined as the ratio of IC50 values in ARPE19 cells divided by the IC50 value of cancer cell line 382 
demonstrates that all the complexes are effective against cancer cell with SI values ranging from 383 
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1.01 to 2.11 (Table S2). Moreover although complex (5) showed more selectivity than other 384 
complexes for HT-29 cancer cell, however its selectivity was significantly lower than cisplatin 385 
where SI value is 25.64 (Figure 6). 386 
3.6. Optimized geometry 387 
The comparison of the geometric parameters (selected bond lengths and bond angles) of 388 
the optimized structures and the crystal structures of the complexes (1, 3, 4, 7 and 8) are listed in 389 
Table S3. All the metal complexes are found to be closed shell structures. The calculated bond 390 
lengths and the bond angles of the complexes are in good agreement with the experimental data 391 
indicating the reliability of the theoretical method (B3LYP/6-31G**/LanL2DZ) used in the 392 
present study. It should be noted that for complexes (3, 4, 7 and 8), the M(1)-N(2) (where M = 393 
Rh/Ir) bond length is slightly longer than the M(1)-N(1) bond length whereas for complex (1), a 394 
reverse pattern has been observed (Table S3). 395 
3.7. Charge distribution 396 
The charges on the individual atoms for the metal complexes obtained from NBO 397 
analysis are listed in Table S4. The charges on the Rh atom in the complexes (1), (3), (5) and (7) 398 
are 0.136, 0.200, 0.216 and 0.214 e whereas the charges on Ir for complexes (2), (4), (6) and (8) 399 
are 0.186, 0.252, 0.268 and 0.214 e respectively. These NBO charges on Rh and Ir are 400 
comparatively lower than their formal charge of +3 which suggests that the ligand transfers their 401 
negative charge to the respective rhodium and iridium metal on complex formation. In metal 402 
complexes (1-8), the charge on Cl ranges between -0.439 e (Complex-1) to -0.394 e (Complex-403 
4). In isolated ligands, the charge on N(1) ranges between -0.416 and –0.417 e whereas for N(2) 404 
it ranges between -0.324 e and -0.348 e. It should be noted that for isolated ligands as well as for 405 
complexes (1-8), the negative charges on N(1) (-0.385, -0.381, -0.372, -0.373, -0.369, -0.398, -406 
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0.368 and -0.373 e) are slightly higher than the charges on N(2) (-0.258, -0.253, -0.284, -0.283, -407 
0.305, -0.297, -0.311 and -0.305 e). On complex formation, the negative charge on the N(1) and 408 
N(2) reduces slightly giving an indication of the charge transfer on Rh and Ir in metal 409 
complexes. The population of the 4d (4dxy, 4dxz, 4dyz, 4dx2-y2 and 4dz2) orbital of Rh complexes 410 
and 5d orbital of Ir complexes are shown in Table S5. The orbital occupations of each orbital 411 
(ndxy, ndxz, ndyz, ndx2-y2 and ndz2) for all the complexes are comparatively higher in rhodium 412 
complexes than iridium complexes. In free Rh(III) and Ir(III) state, the population of ndxy, ndxz and 413 
ndyz  are 2.0, 2.0 and 2.0 e and the other two orbitals remain vacant. But on complex formation, the 414 
population on ndxy, ndxz and ndyz orbital gets reduced whereas the ndx2-y2 and ndz2 orbitals gain 415 
some population as indicated in Table S5. For most of the complexes, the population of 4d and 416 
5d orbital containing the same ligand follow similar pattern of filling, except for the complexes 417 
containing ligand L1 where the ndxz orbital population is slightly lower and ndx2-y2 is higher as 418 
compared to the other complexes. 419 
3.8. Frontier molecular orbitals and absorption spectra 420 
The molecular orbital representation of the complexes along with their HOMO, LUMO 421 
energies and HOMO-LUMO energy gaps are shown in Figure 7. The HOMO-LUMO energy gap 422 
can be used as an important parameter in analyzing the chemical reactivity and kinetic stability 423 
of a molecule. This energy gap is also related to the hardness/softness of a chemical species [53]. 424 
The lower HOMO-LUMO energy gap is a suitable condition where a molecule can be excited 425 
easily and thereby increasing its reactivity and decreasing its kinetic stability whereas higher 426 
energy gap can lead to more kinetic stability but less reactivity. The HOMO-LUMO energy gaps 427 
for all the complexes (1-8) are found to be 3.20, 2.98, 3.63, 3.46, 3.61, 3.60, 3.68 and 3.59 eV 428 
respectively. The gap is slightly lower for the iridium complexes as compared to rhodium 429 
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complexes containing the same ligand indicating the reactivity of Ir complexes over the 430 
complexes containing Rh metal. The % contribution of molecular orbital analysis as shown in 431 
Table S6, predicts that the most percentage of HOMO is located on the ligand itself except for 432 
complex (2) and (8) where as it is mostly present on the Ir metal. On the other hand, LUMO is 433 
located on the ligand for complexes (1) (about 97%), (2) (91%), (4) (89%), (6) (92%) and (8) 434 
(69%) whereas for complexes (3) (40%), (5) (35%) and (7) (38%), it is located on the Rh metal. 435 
The electronic absorption spectra were calculated using the TD-DFT method in 436 
acetonitrile solvent employing PCM model. The calculated and the experimental absorption data, 437 
HOMO-LUMO energy gaps, and the character of electronic transitions are listed in Table 4. The 438 
H→L transitions for complexes (1), (4) and (6) occurring at 417, 444 and 441 nm corresponds to 439 
ILCT character, for complexes (2) and (8) at 463 and 440 nm corresponds to MLCT character 440 
whereas for complexes (3), (5) and (7) at 532, 519 and 518 nm corresponds to LMCT character. 441 
These MLCT character can be assigned for dpi(M)→pi∗(L) transitions whereas the ILCT 442 
character are for pi→pi∗ transitions. It should be noted that all LMCT transitions are occurring at 443 
higher wavelength regions (i.e. > 500 nm). In good agreement with the experimental data, the 444 
TD-DFT calculations shows few MLCT transitions at 358 nm complex (2), 332 nm, complex 445 
(4), 334 nm complex (6) and 372, 358 nm complex (8). However, in the range between 340-400 446 
nm, few LMCT, ILCT and LLCT transitions have also been observed (Table 4). 447 
4. Conclusion 448 
In summary, we have synthesized four new azine Schiff-base ligands and its rhodium and 449 
iridium half-sandwich complexes. All these complexes and ligands were full characterized by 450 
various spectroscopic techniques. The ligands under study preferably bind to the metal in a 451 
bidentate N∩N fashion using pyridine and one azine nitrogen atom. Our attempt to synthesize 452 
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dinuclear rhodium and iridium complexes with NNʹ and NO bonding was however unsuccessful 453 
irrespective of molar ratio of metal to ligand where as in the presence of base, it leads to 454 
decomposition of the reaction. These complexes possess some important intramolecular and 455 
intermolecular hydrogen bonding and also possess some weak non-covalent interactions, 456 
particularly C-H·····Cl and C-H·····pi interactions. Chemosensitivity activity of the complexes 457 
against HT-29 cancer cell demonstrates that the complexes are active however complex (5) was 458 
found to be the most potent among all other complexes. Theoretical studies reveal that the 459 
HOMO-LUMO energy gap is lower for iridium complexes indicating better reactivity over the 460 
rhodium complexes. TD-DFT calculations were carried out in order to evaluate the electronic 461 
transitions occurring in the metal complexes, which are in good agreement with the experimental 462 
results.  The charge distribution analysis (using NBO analysis) of these complexes helps to 463 
understand how the charges on nitrogen atom (which are coordinating to the metal) are 464 
delocalized on complex formation. Especially, the NBO charges, on rhodium and iridium 465 
confirm that the ligands transfer their negative charge to the respective metal on complex 466 
formation. The lower HOMO-LUMO energy gap leads to greater chemical reactivity but lesser 467 
kinetic stability and vice versa. Furthermore, the nature of HOMO and LUMO illustrate the 468 
electronic origin of the lowest energy transition and the resulting electronic reorganization. 469 
Moreover, the molecular orbital analysis was helpful to understand and locate the % contribution 470 
of HOMO and LUMO on different fragments of the complexes, which is otherwise not possible 471 
to predict from experimental data.  472 
Acknowledgements 473 
Sanjay Adhikari and Dipankar Sutradhar thanks UGC, New Delhi, India for providing financial 474 
assistance in the form of university fellowship (UGC-Non-Net). We thank DST-PURSE 475 
  
23 
 
SCXRD, NEHU-SAIF, Shillong, India for providing Single crystal X-ray analysis and other 476 
spectral studies. AKC thanks Computer centre, NEHU, for computational facilities. 477 
Supplementary material 478 
CCDC 1477976 (1), 1477977 (3), 1477978 (4), 1477979 (7) and 1477980 (8) contains 479 
the supplementary crystallographic data for this paper. These data can be obtained free of charge 480 
via www.ccdc.cam.ac.uk/data_request/cif, by e-mailing data_request@ccdc.cam.ac.uk, or by 481 
contacting The Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, 482 
UK; Fax: +44 1223 336033. 483 
 484 
References 485 
[1] G. Gasser, I. Ott, N. Metzler-Nolte, J. Med. Chem. 54 (2011) 3. 486 
[2] L. Ronconi, P.J. Sadler, Coord. Chem. Rev. 251 (2007) 1633. 487 
[3] Y.K. Yan, M. Melchart, A. Habtemariam, P.J. Sadler, Chem. Commun. (2005) 4764. 488 
[4] B. Therrien, Coord. Chem. Rev. 253 (2009) 493. 489 
[5] U. Sliwinska, F.P. Pruchnik, S. Ulaszewski, M. Latocha, D. Nawrocka-Musial, 490 
Polyhedron 29 (2010) 1653. 491 
[6] M.A. Scharwitz, I. Ott, Y. Geldmacher, R. Gust, W.S. Sheldrick, J. Organomet. Chem. 492 
693 (2008) 2299. 493 
[7] M.A. Nazif, J.-Amade Bangert, I. Ott, R. Gust, R. Stoll, W.S. Sheldrick, J. Biol. Inorg. 494 
Chem. 103 (2009) 1405. 495 
[8] M. Gras. B. Therrien, G. Suss-Fink, A. Casini, F. Edafe, P.J. Dyson, J. Organomet. 496 
Chem. 695 (2010) 1119. 497 
  
24 
 
[9] Y. Geldmacher, M. Oleszak, W.S. Sheldrick, Inorg. Chim. Acta 393 (2012) 84. 498 
[10] R. Bieda, I. Ott, M. Dobroschke, A. Prokop, R. Gust, W.S. Sheldrick, J. Biol. Inorg. 499 
Chem. 103 (2009) 698. 500 
[11] Z. Liu, P.J. Sadler, Acc. Chem. Res. 47 (2014) 1174. 501 
[12] G. Gupta, A. Garci, B.S. Murray, P.J. Dyson, G. Fabre, P. Trouillas, F. Giannini, J. 502 
Furrer, G. Suss-Fink, B. Therrien, Dalton Trans. 42 (2013) 15457. 503 
[13] S. Mukhopadhyay, R.K. Gupta, R.P. Paitandi, N.K. Rana, G. Sharma, B. Koch, L.K. 504 
Rana, M.S. Hundal, D.S. Pandey, Organometallics 34 (2015) 4491. 505 
[14] J. De Pasquale, I. Nieto, L.E. Reuther, C.J. H-Gervasoni, J.J. Paul, V. Mochalin. M. 506 
Zeller, C.M. Thomas, A.W. Addison, E.T. Papish, Inorg. Chem. 52 (2013) 9175. 507 
[15] Y. Geldmacher, K. Splith, I. Kitanovic, H. Alborzinia, S. Can, R. Rubbiani, M.A. Nazif, 508 
P. Wefelmeier, A. Prokop, I. Ott, S. Wolfl, I. Neundorf, W.S. Sheldrick, J. Biol. Inorg. 509 
Chem. 17 (2012) 631. 510 
[16] Z. Liu, I. Romero-Canelon, A. Habtemariam, G.J. Clarkson, P.J. Sadler, Organometallics 511 
33 (2014) 5324. 512 
[17] Z. Liu, A. Habtemariam, A.M. Pizarro, S.A. Fletcher, A. Kisova, O. Vrana, L. Salassa, 513 
P.C.A. Bruijnincx, G.J. Clarkson, V. Brabec, P.J. Sadler, J. Med. Chem. 54 (2011) 3011. 514 
[18] J. Safari, S. Gandomi-Ravandi, RSC Adv. 4 (2014) 46224. 515 
[19] Z. Xu, L.K. Thompson, D.O. Miller, Inorg. Chem. 36 (1997) 3985. 516 
[20] M. Ghedini, A.M.M. Lanfredi, F. Neve, A. Tiripicchio, J. Chem. Soc. Chem. Commun. 517 
(1987) 847. 518 
[21] E.-Q. Gao, S.-Q. Bai, Y.-F. Yue, Z.-M. Wang, C.-H. Yan, Inorg. Chem. 42 (2003) 3642. 519 
[22] Y.-F. Yue, C.-J. Fang, E.-Q. Gao, C. He, S.-Q. Bai, S. Xu, C.-H. Yan, J. Mol. Struct. 875 520 
  
25 
 
(2008) 80. 521 
[23] Z. Xu, L.K. Thompson, D.A. Black, C. Ralph, D.O. Miller, M.A. Leech, J.A.K. Howard, 522 
J. Chem. Soc., Dalton Trans. (2001) 2042. 523 
[24] K.T. Prasad, G. Gupta, A.V. Rao, B. Das, K.M. Rao, Polyhedron 28 (2009) 2649. 524 
[25] G. Gupta, S. Gloria, S.L. Nongbri, B. Therrien, K.M. Rao, J. Organomet. Chem. 696 525 
(2011) 2014. 526 
[26] D.D. Perrin, W.L.F. Armarego, Purification of Laboratory Chemicals, fourth ed., 527 
Butterworths Heinemann, London, 1996. 528 
[27] C. White, A. Yates, P.M. Maitlis, D.M. Heinekey, Inorg. Synth. 29 (2007) 228. 529 
[28] G.M. Sheldrick, Acta Crystallogr. Sect. A 64 (2008) 112. 530 
[29] G.M. Sheldrick Acta Crystallogr. Sect. C 71 (2015) 3. 531 
[30] L.J. Farrugia, J. Appl. Crystallogr. 32 (1999) 837. 532 
[31] R.M. Phillips, P.B. Hulbert, M.C. Bibby, N.R. Sleigh, J.A. Double, Br. J. Cancer. 533 
65 (1992) 359. 534 
[32] R.A. Kaner, S.J. Allison, A.D. Faulkner, R.M. Phillips, D.I. Roper, S.L. Shepherd, D.H. 535 
Simpson, N.R. Waterfield, P. Scott, Chem. Sci. 7 (2016) 951. 536 
[33] M.J. Frisch et al., GAUSSIAN 09, Revision C.01, Gaussian Inc, Walling-ford, CT, 2009. 537 
[34] A.D. Becke, J. Chem. Phys. 98 (7) (1993) 5648. 538 
[35] C. Lee, W. Yang, R.G. Parr, Phys. Rev. B 37 (2) (1988) 785. 539 
[36] E. Cances, B. Mennucci, J. Tomasi, J. Chem. Phys. 107 (1997) 3032. 540 
[37] A.E. Reed, L.A. Curtiss, F. Weinhold, Chem. Rev. 88 (1988) 899. 541 
[38] M.E. Casida, in: J.M. Seminario (Ed.), Recent Developments and Applications in Modern 542 
Density Functional Theory, Theoretical and Computational Chemistry, vol. 4, Elsevier, 543 
Amsterdam, 1996. 544 
  
26 
 
[39] L. Skripnikov, Chemissian v4.36, A computer program to analyse and visualise quantum-545 
chemical calculations, 2015. 546 
[40] F. Weldon, L. Hammarstrom, E. Mukhtar, R. Hage, E. Gunneweg, J.G. Haasnoot, J. 547 
Reedijk, W.R. Browne, A.L. Guckian, J.G. Vos, Inorg. Chem. 43 (2004) 4471. 548 
[41] C.U. Dueke-Eze, T.M. Fasina, M.J. Mphahlele, Asian J. Chem. 25 (2013) 8505. 549 
[42] S.D. Dwivedi, A.K. Singh, S.K. Singh, S. Sharma, M. Chandra, D.S. Pandey, Eur. J. 550 
Inorg. Chem. (2008) 5666. 551 
[43] P. Govindaswamy, Y.A. Mozharivskyj, K.M. Rao, Polyhedron 24 (2005) 1710. 552 
[44] D.L. Davies, J. Fawcett, R. Krafczyk, D.R. Russell, J. Organomet. Chem. 581 (1997) 553 
545. 554 
[45] P. Chellan, K.M. Land, A. Shokar, A. Au, S.H. An, D. Taylor, P.J. Smith, T. Riedel, P.J. 555 
Dyson, K. Chibale, G.S. Smith, Dalton Trans. 43, (2014) 513. 556 
[46] G. Gupta, G. Sharma, B. Koch, S. Park, S.S. Lee, J. Kim, New.J.Chem. 37 (2013) 2573. 557 
[47] K.S. Singh, Y.A. Mozharivskyj, C. Thone, M.R. Kollipara, J. Organomet. Chem. 690 558 
(2005) 3720. 559 
[48] N.R. Palepu, S.L. Nongbri, J.R. Premkumar, A.K. Verma, K. Bhattacharjee, S.R. Joshi, 560 
S. Forbes, Y.A. Mozharivskyj, R. Thounaojam, K. Aguan, M. R. Kollipara, J. Biol. Inorg. 561 
Chem. 20 (2015) 619. 562 
[49] S.K. Singh, M. Chandra, D.S. Pandey, M.C. Puerta, P. Valerga, J. Organomet. Chem. 689 563 
(2004), 3612. 564 
[50] R. Payne, P. Govender, B. Therrien, C.M. Clavel, P.J. Dyson, G.S. Smith, J. Organomet. 565 
Chem. 729 (2013) 20. 566 
[51] A.P. Walsh, W.W. Brennessel, W.D. Jones, Inorg. Chim. Acta 407 (2013) 131. 567 
  
27 
 
[52] M. Kalidasan, S.H. Forbes, Y. Mozharivskyj, M.R. Kollipara, Inorg. Chim. Acta 421 568 
(2014) 218. 569 
[52] Y. Hanifehpour, B. Mirtamizdoust, S.W. Joo, J Inorg Organomet Polym. 22 (2012) 916. 570 
  
28 
 
 571 
Scheme-1 Synthesis of 2-pyridylamidrazone 572 
 573 
 574 
Scheme-2 Preparation of ligands (L1-L4) 575 
 576 
 577 
Scheme-3 Preparation of metal complexes (1-8) 578 
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 579 
Figure 1 ORTEP diagram of complex [Cp*RhCl(L1)Cl]PF6 (1) with 50% probability thermal 580 
ellipsoids. Hydrogen atoms and counter ions are omitted for clarity. 581 
 582 
Figure 2 (a) ORTEP diagram of complex [Cp*RhCl(L2)Cl]PF6 (3) and (b) ORTEP diagram of 583 
complex [Cp*IrCl(L2)Cl]PF6 (4) with 50% probability thermal ellipsoids. Hydrogen atoms and 584 
counter ions are omitted for clarity. 585 
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 586 
  587 
 8 
 589 
Figure 3 (a) ORTEP diagram of complex [Cp*Rh(L4)Cl]PF6 (7) and (b) ORTEP diagram, of 590 
complex [Cp*IrCl(L4)Cl]PF6 (8) with 50% probability thermal ellipsoids. Hydrogen atoms and 591 
counter ions are omitted for clarity. 592 
 593 
Figure 4 Crystal structure of complexes (3) and (4) showing intramolecular hydrogen bonding. 594 
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 595 
Figure 5 Response of HT-29 (human colorectal cancer) to compounds (1-8) and cisplatin. Cell 596 
were exposed to compounds (1-8) for 96 hours. Each value represents the mean ± standard 597 
deviation from three independent experiments. 598 
 599 
Figure 6 Graph showing selectivity index of complex 5 and cisplatin against HT-29 cancer cell 600 
line. The selectivity index is defined as the IC50 of ARPE19 cell divided by the IC50 of  tumour 601 
cell line.602 
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 603 
 604 
Figure 7 HOMO, LUMO energies and their energy gap of complexes (1–8)605 
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Table 1. Crystal structure data and refinement parameters of complexes. 606 
Structures were refined on F02: wR2 = [Σ[w(F02 - Fc2)2] / Σw(F02)2]1/2, where w-1 = [Σ(F02)+(aP)2+bP] and P = [max(F02, 0)+2Fc2]/3. 607 
Complexes [1] PF6 [3] PF6 [4] PF6 [7] PF6 [8] PF6 Cl 
Empirical formula C24H29ClN4O2F6PRh C23H27ClF6N4OPRh C23H27ClF6N4OPIr C24H29ClF6N4PRh C24H29Cl2F6N4PIr 
Formula weight 688.84 658.82 748.11 656.84 781.58 
Temperature (K) 298(2)  293(2) 293(2) 293(2) 293(2) 
Wavelength (Å) 0.71073 0.71073 0.71073 0.71073 0.71073 
Crystal system triclinic monoclinic monoclinic monoclinic triclinic 
Space group P ͞1 P21/c P21/c P21/c P ͞1 
a (Å)/α (°) 8.3893(7)/89.370(6) 10.6710(6)/90 10.7019(5)/90  38.850(5)/90 7.9976(4)/87.496 
b (Å)/β (°) 10.5533(7)/86.439(6) 17.0730(8)/92.708(4). 17.0860(9)/93.062(4) 7.9488(5)/98.027(4) 12.4774(4)/82.086(4) 
c (Å)/γ (°) 16.6554(11)/71.182(7) 14.5390(8)/90 14.6118(9)/90 28.562(4)/90 14.6442(6)/72.596(4) 
Volume (Å3) 1393.00(18) 2645.8(2)  2668.0(2) 1344.83(10) 1381.15(10) 
Z 2 4 4 2 2 
Density (calc) (Mg/m-3) 1.642  1.654 1.862 1.622 1.879 
Absorption coefficient (µ) (mm-1) 0.836 0.874 5.231 0.857 5.148 
F(000) 696 1328 1456 664 762 
Crystal size (mm3) 0.23 x 0.21 x 0.21 0.21 x 0.19 x 0.04 0.23 x 0.23 x 0.21 0.22 x 0.20 x 0.120 0.19 x 0.12 x 0.09 
Theta range for data collection 3.174 to 28.654°. 3.33 to 26.73°. 3.31 to 26.37°. 3.386 to 28.842°. 3.23 to 26.37°. 
Index ranges -11<=h<=10, -12<=k<=13, -
22<=l<=20 
-13<=h<=10, -10<=k<=21, -
12<=l<=18 
-13<=h<=7, -21<=k<=19, -
16<=l<=18 
-9<=h<=9, -12<=k<=22, -
14<=l<8 
-8<=h<=9, -15<=k<=15, -
17<=l<18 
Reflections collected 10811 9506 10081 5614 7889 
Independent reflections 6286 [R(int) =0.0717] 5375 [R(int) = 0.0268] 5422 [R(int) = 0.0277] 4000 [R(int) = 0.0268] 5335 [R(int) = 0.0296] 
Completeness to theta = 25.00° 99.57 % 99.5 %  99.2 % 99.2 %  94.8 %  
Absorption correction Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Refinement method Full-matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
Data/restraints/parameters 6286/0/362 2375/0/330 5422/0/340 4000/1/340 5335/0/349 
Goodness-of-fit on F2 1.197 1.063 1.026 1.041 1.046 
Final R indices [I>2sigma(I)] R1 = 0.0703, wR2 = 0.1706 R1 = 0.0440, wR2 = 0.0895 R1 = 0.0340, wR2 = 0.0630 R1 = 0.0394, wR2 = 0.0822 R1 = 0.0368, wR2 = 0.0875 
R indices (all data) R1 = 0.0855, wR2 = 0.1772 R1 = 0.0592, wR2 = 0.0968 R1 = 0.0500, wR2 = 0.0683 R1 = 0.0462, wR2 = 0.0858 R1 = 0.0431, wR2 = 0.0912 
Largest diff. peak and hole (e.Å-3) 0.583 and -0.461  0.520 and -0.543 1.102and -1.143 0.512 and -0.478 1.828 and -1.071 
CCDC No. 1477976 1477977 1477978 1477979 1477980 
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Table-2. Selected hydrogen bonding distances (Å) and angles (°) of complexes 3 and 4. 608 
Complexes D-H·····A H····A (Å) D·····A (Å) D·····H (Å) ∠D─H···A(°) 
3 O(1)-H(1A)·····N(4) 1.916 2.638 0.820 146.39 
 N(3)-H(3A)·····N(4) 2.323 2.624 0.860 100.76 
4 O(1)-H(1A)·····N(4) 1.908 2.634 0.820 146.90 
 N(3)-H(3A)·····N(4) 2.328 2.629 0.860 100.78 
 609 
Table-3 Response of HT-29 (human colorectal cancer) to complexes (1-8) and cisplatin. Each 610 
value represents the mean ± standard deviation from three independent experiments. 611 
Complexes IC50 (µM) 
HT-29 ARPE-19 
1 56.95 ± 11.76 85.31 ± 14.86 
2 89.42 ± 18.33 93.45 ± 11.34 
3 82.32 ± 15.55 83.03 ± 14.76 
4 96.93 ± 5.31 >100 
5 46.17 ± 12.78 97.39 ± 4.53 
6 83.74 ± 28.17 >100 
7 93.16  ± 11.84 >100 
8 88.09 ± 20.63 >100 
Cisplatin 0.25 ± 0.11 6.41 ± 0.95 
 612 
Table 4. The energy gap, theoretical and experimental absorption bands, electronic transitions 613 
and dominant excitation character for various singlet states of the complexes (1-8) calculated 614 
with TD-DFT method. 615 
The most 
important orbital 
excitations 
Calculated 
λ (nm) 
Energy 
gap E 
(eV) 
Oscillator 
strength 
(f) 
Dominant excitation 
Character 
Experimental 
λ (nm) 
Complex (1) 
H→L 417.16 3.20 0.2051 L1→L1(ILCT)  
H-2→L 359.64 3.53 0.0542 Cl→L1(LLCT) 352.21 
H→L+2 355.41 4.03 0.0120 L1→L1(ILCT)  
H-4→L+2 338.40 4.89 0.0139 L1→L1(ILCT)  
H-1→L+4 278.91 4.73 0.0248 L1→L1(ILCT) 276.0 
H-6→L 282.81 4.54 0.0073 L1→L1(ILCT)  
H-6→L+2 275.41 5.37 0.0050 L1→L1(ILCT)  
H-11→L 235.62 5.08 0.0216 Rh→L1(MLCT) 233.3 
H-5→L+4 233.62 5.74 0.0480 Cl→L1(LLCT)  
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H-6→L+3 232.46 5.46 0.0105 L1→L1(ILCT)  
Complex (2) 
H→L 462.76 2.98 0.0644 Ir→L1(MLCT)  
H→L+3 358.38 4.64 0.0191 Ir→Cp*(MLCT) 347.0 
H-4→L 340.55 4.01 0.0075 L1→L1(ILCT)  
H-5→L+1 273.73 5.11 0.0470 Cp*→L1(LLCT) 266.0 
H-2→L+4 266.79 5.33 0.1540 L1→Ir(LMCT)  
Complex (3) 
H→L 532.04 3.63 0.0087 L2→Rh(LMCT)  
H-2→L+1 348.95 4.11 0.0369 L2→L2(ILCT) 344.10 
H→L+2 345.72 3.84 0.0128 L2→Rh(LMCT)  
H-1→L+2 344.68 4.10 0.0089 Cl+L2→Rh(LMCT)  
H-3→L 336.07 4.24 0.0047 Cl→Rh(LMCT)  
H→L+4 289.42 4.85 0.0063 L2→L2(ILCT) 286.1 
H-6→L 285.32 5.14 0.0163 Cl+L2→Rh(LMCT)  
H-5→L+1 282.59 4.98 0.0391 L2→L2(ILCT)  
H-4→L+4 237.16 5.74 0.0422 L2→L2(ILCT) 234.30 
H-5→L+3 234.58 5.74 0.0161 L2→L2(ILCT)  
Complex (4) 
H→L 444.09 3.46 0.0355 L2→L2(ILCT)  
H-2→L 362.56 3.91 0.0077 L2→L2(ILCT) 346.1 
H-1→L+1 332.29 3.80 0.0076 Rh+L2→L2(MLCT/ILCT)  
H→L+3 329.46 4.48 0.0468 L2→L2(ILCT)  
H-4→L 324.35 4.53 0.0265 Cl+Cp*→L2(LLCT)  
H-4→L+2 294.35 5.47 0.0164 Cl+Cp*→L2(LLCT) 292.21 
H-1→L+2 288.71 4.74 0.0048 Rh+L2→Rh+L2  
H-8→L+3 212.19 6.47 0.0387 L2→L2(ILCT) 210.9 
H-6→L+4 210.71 6.56 0.0399 Cl→L2(LLCT)  
H-2→L+5 210.22 6.26 0.0669 L2→L2(ILCT)  
Complex (5) 
H→L 519.01 3.61 0.0076 L3→Rh(LMCT)  
H-2→L+2 338.46 4.30 0.0120 Cl→L3(LLCT) 332.0 
H-4→L+1 326.16 4.56 0.0052 L3→Rh(LMCT)  
H-1→L+4 271.36 5.01 0.265 L3→L3(ILCT) 268.0 
H-2→L+4 267.30 5.21 0.0177 Cl→L3(LLCT)  
H-5→L+4 232.84 5.83 0.0498 L3→L3(LLCT) 229.0  
H-10→L+2 229.44 6.14 0.0127 Rh+L3→L3(MLCT/ILCT)  
Complex (6) 
H→L 441.76 3.60 0.0160 L3→L3(ILCT)  
H-2→L+1 334.33 4.45 0.0109 Ir→L3(MLCT) 330.0 
H-1→L+1 328.24 4.33 0.1160 L3→L3(ILCT)  
H-7→L 268.58 5.42 0.0159 Ir→L3(MLCT) 256.0 
H-6→L 264.64 5.25 0.0304 Cl→L3(LLCT)  
H-1→L+4 260.56 5.17 0.0350 L3→L3(ILCT)  
Complex (7) 
H→L 518.07 3.68 0.0071 L4→Rh(LMCT)  
H-1→L 448.90 4.05 0.0132 Cl→Rh(LMCT) 400.0 
H-1→L+1 397.25 4.09 0.0148 Cl→Rh(LMCT)  
H-1→L+4 269.94 5.23 0.0297 Cl→L4(LLCT) 265.0 
H-2→L+3 262.52 5.20 0.0465 Cl→L4(LLCT)  
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H→L+5 231.04 5.66 0.0547 L4→L4(ILCT) 229.0 
Complex (8) 
H→L 439.65 3.59 0.0196 Ir→L4(MLCT)  
H-1→L+2 371.55 4.79 0.0381 Ir→L4(MLCT) 361.0 
H-1→L 358.22 4.0 0.0349 Ir→L4(MLCT)  
H-2→L+3 257.57 5.29 0.0359 Cl→Cp*(LLCT) 256.0 
H-4→L+3 255.65 5.61 0.0142 L4→Cp*(LLCT)  
 616 
